Amylin Pharmaceuticals, Inc. (AMLN) announced new clinical data from the European Exenatide or EUREXA study that showed treatment with BYETTA injection resulted in greater glycemic durability and overall glycemic control than Amaryl in patients with type 2 diabetes uncontrolled on metformin alone.
The company also noted that patients treated with BYETTA have experienced reductions in body weight and fewer hypoglycemic events.
The company said these clinical study findings are being presented at the 2012 ADA/The Lancet Symposium at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia and will be published in the diabetes-themed issue of The Lancet.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.